Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat adults with moderate-to-severe bullous pemphigoid: Paris Wednesday, March 25, 2026, 09:00 Hrs [IST] T ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results show ...

Dhaka, the densely populated capital of Bangladesh, ranked fifth among the world’s most polluted cities on Wednesday morning, ...

This week Dr Ray O’Connor takes a look at the potential role of medication and vaccination on the prevention of dementia and ...

After generating interest from the likes of Pfizer and GSK, Quotient Therapeutics’ somatic genomics platform has attracted ...

Dhaka, March 25 -- Dhaka, the densely populated capital of Bangladesh, ranked fifth among the world's most polluted cities on Wednesday morning, recording an Air Quality Index (AQI) of 164 at 8:40 am.

SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement ...

It’s time once again for Fierce Pharma Marketing’s annual #FierceMadness tournament. This time around, we're watching 64 ...